Effect of short-term interferon-beta treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23

Kurtuncu M., Tuzun E., TURKOGLU R., PETEK-BALCI B., Icoz S., Pehlivan M., ...More

CYTOKINE, vol.59, no.2, pp.400-402, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 2
  • Publication Date: 2012
  • Doi Number: 10.1016/j.cyto.2012.05.004
  • Journal Name: CYTOKINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.400-402
  • Keywords: Multiple sclerosis, Cytokine, Interleukins, Th17, Th1, AUTOIMMUNE ENCEPHALOMYELITIS, MS PATIENTS, THERAPY, CELLS, INTERLEUKIN-12, RESPONDERS, DISEASE, GAMMA
  • Istanbul University Affiliated: Yes

Abstract

Therapeutic effect of interferon-beta (IFN-beta) treatment has been associated with modulation of the balance between Th1, Th17, Th2 and regulatory T (Treg) cells, whereas the impact of disease modifying drugs on Th9-immunity in multiple sclerosis (MS) has not been studied. To investigate the short-term effects of IFN-beta treatment on cytokines in MS, we determined serum levels of IL-17, IL-23, IL-10, IL-4, IFN-gamma, IL-9 and TGF-beta in relapsing remitting MS patients before and 2 months after IFN-beta treatment by ELISA. MS patients showed increased IL-17, IL-23 and IL-4 levels and decreased IL-9 levels as compared to healthy controls. IFN-beta treatment only reduced IL-17 and IL-23 levels, whereas the levels of other cytokines remained unchanged. IFN-beta treatment appears to exert its earliest therapeutic effect on Th17-immunity. The influence of IL-9 on MS pathogenesis needs to be further studied. (C) 2012 Elsevier Ltd. All rights reserved.